showed an interesting trend in ARDS mortality comparing metformin users with non-users (42.4% versus 55.3%, p = ns), even though metformin was discontinued on admission in the cohort examined ( Jo et al., 2017 ).
1
—
—
showed an interesting trend in ARDS mortality comparing metformin users with non-users (42.4% versus 55.3%, p = ns), even though metformin was discontinued on admission in the cohort examined ( Jo et al., 2017 ).